Pregabalin Capsule
Product Images NDC 71205-694

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-694). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of Pregabalin, showing its molecular layout with a carboxyl group (CO2H) and an amine group (NH2).*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing percent of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating response rates across increasing pain improvement thresholds.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It shows two lines: one for Pregabalin 100 mg three times a day and one for placebo, illustrating patient response over a range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for different Pregabalin dosages (75 mg, 150 mg, 300 mg taken two times a day) and placebo. The graph compares treatment effects on pain improvement over a range from 0% to 100%.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends in patient improvement across pain reduction percentages.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph comparing the percent of patients improved over a range from 0 to 100 days from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends of patient improvement percentages over time with distinct line styles for each group and includes vertical reference lines at around days 30 and 50.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) across different dosing regimens of Pregabalin versus placebo in two clinical studies, labeled Study E1 and Study E3, showing higher responder rates with increasing Pregabalin doses up to 600 mg/day, administered either twice daily (BID) or three times daily (TID).*

FDA Label Image

Figure 7 (Pregabalin 08)

A dose-response graph showing seizure reduction as median percentage change from baseline versus dose in mg/day. The chart compares seizure reduction across three studies with different dosing regimens (BID and TID). Symbols represent study data points with p-values indicating statistical significance.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It includes curves for Pregabalin daily doses of 300 mg, 450 mg, and 600 mg, as well as a placebo group, showing variation in patient improvement across doses.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR (loss to response) over 180 days between two groups: Pregabalin and Placebo. The chart shows higher retention in the Pregabalin group throughout the study period.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph showing the percent of subjects improved from baseline to Week 12 measured by BOCF for Pregabalin versus Placebo. The x-axis represents the percent improved, ranging from more than 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 100 percent. Two lines depict the improvement trends for Pregabalin (solid line) and Placebo (dashed line).*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph depicting the percentage of subjects improved over time, comparing Pregabalin and placebo from baseline to week 16 BOCF. The x-axis shows percent improvement, and the y-axis represents the percent of subjects improved, with two separate curves for Pregabalin and placebo.*

FDA Label Image

71205-694-60 (Pregabalin 17)

Label for Pregabalin 150 mg oral capsules in a #60 count package by Proficient Rx LP. Each capsule contains 150 mg of pregabalin. The label includes the National Drug Code (NDC 71205-694), dosing instructions to dispense the medication guide, and storage conditions at 25°C (77°F). Packaged by Proficient Rx LP, Thousand Oaks, CA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.